BackgroundLung ultrasound (LUS) offers advantages over traditional imaging for diagnosing pulmonary conditions, with superior accuracy compared to chest X-ray and similar performance to CT at lower cost. Despite these benefits, widespread adoption is limited by operator dependency, moderate interrater reliability, and training requirements. Deep learning (DL) could potentially address these challenges, but development of effective algorithms is hindered by the scarcity of comprehensive image repositories with proper metadata. MethodsWe created an open-source dataset of LUS images derived a multi-center study involving N=226 adult patients presenting with respiratory symptoms to emergency departments between March 2020 and April 2022. Images were acquired using a standardized scanning protocol (12-zone or modified 8-zone) with various point-of-care ultrasound devices. Three blinded researchers independently analyzed each image following consensus guidelines, with disagreements adjudicated to provide definitive interpretations. Videos were pre-processed to remove identifiers, and frames were extracted and resized to 128x128 pixels. ResultsThe dataset contains 1,874 video clips comprising 303,977 frames. Half of the participants (50%) had COVID-19 pneumonia. Among all clips, 66% contained no abnormalities, 18% contained B-lines, 4.5% contained consolidations, 6.4% contained both B-lines and consolidations, and 5.2% had indeterminate findings. Pathological findings varied significantly by lung zone, with anterior zones more frequently normal and less likely to show consolidations compared to lateral and posterior zones. DiscussionThis dataset represents one of the largest annotated LUS repositories to date, including both COVID-19 and non-COVID-19 patients. The comprehensive metadata and expert interpretations enhance its utility for DL applications. Despite limitations including potential device-specific characteristics and COVID-19 predominance, this repository provides a valuable resource for developing AI tools to improve LUS acquisition and interpretation.

Predicting long-term functional outcomes for individuals with stroke is a significant challenge. Solving this challenge will open new opportunities for improving stroke management by informing acute interventions and guiding personalized rehabilitation strategies. The location of the stroke is a key predictor of outcomes, yet no clinically deployed tools incorporate lesion location information for outcome prognostication. This study responds to this critical need by introducing a fully automated, three-stage neuroimaging processing and machine learning pipeline that predicts personalized outcomes from clinical imaging in adult ischemic stroke patients. In the first stage, our system automatically processes raw DICOM inputs, registers the brain to a standard template, and uses deep learning models to segment the stroke lesion. In the second stage, lesion location and automatically derived network features are input into statistical models trained to predict long-term impairments from a large independent cohort of lesion patients. In the third stage, a structured PDF report is generated using a large language model that describes the strokes location, the arterial distribution, and personalized prognostic information. We demonstrate the viability of this approach in a proof-of-concept application predicting select cognitive outcomes in a stroke cohort. Brain-behavior models were pre-trained to predict chronic impairment on 28 different cognitive outcomes in a large cohort of patients with focal brain lesions (N=604). The automated pipeline used these models to predict outcomes from clinically acquired MRIs in an independent ischemic stroke cohort (N=153). Starting from raw clinical DICOM images, we show that our pipeline can generate outcome predictions for individual patients in less than 3 minutes with 96% concordance relative to methods requiring manual processing. We also show that prediction accuracy is enhanced using models that incorporate lesion location, lesion-associated network information, and demographics. Our results provide a strong proof-of-concept and lay the groundwork for developing imaging-based clinical tools for stroke outcome prognostication.

Accurate estimation of cerebral amyloid-{beta} (A{beta}) burden is critical for early detection and risk stratification in Alzheimers disease (AD). While A{beta} positron emission tomography (PET) remains the gold standard, its high cost, invasive nature and limited accessibility hinder broad clinical application. Blood-based biomarkers offer a non-invasive and cost-effective alternative, but their standalone predictive accuracy remains limited due to biological heterogeneity and limited reflection of central nervous system pathology. Here, we present a high-precision, multimodal prediction machine learning model that integrates plasma biomarkers, brain structural magnetic resonance imaging (sMRI) features, diffusion tensor imaging (DTI)-derived structural connectomes, and genetic risk profiles. The model was trained on 150 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI) and externally validated on 111 participants from the SILCODE cohort. Multimodal integration substantially improved A{beta} prediction, with R{superscript 2} increasing from 0.515 using plasma biomarkers alone to 0.637 when adding imaging and genetic features. These results highlight the potential of this multimodal machine learning approach as a scalable, non-invasive, and economically viable alternative to PET for estimating A{beta} burden.

Background and ObjectivesBottom-of-sulcus dysplasia (BOSD) is a diagnostically challenging subtype of focal cortical dysplasia, 60% being missed on patients first MRI. Automated MRI-based detection methods have been developed for focal cortical dysplasia, but not BOSD specifically. Use of FDG-PET alongside MRI is not established in automated methods. We report the development and performance of an automated BOSD detector using combined MRI+PET data. MethodsThe training set comprised 54 mostly operated patients with BOSD. The test sets comprised 17 subsequently diagnosed patients with BOSD from the same center, and 12 published patients from a different center. 81% patients across training and test sets had reportedly normal first MRIs and most BOSDs were <1.5cm3. In the training set, 12 features from T1-MRI, FLAIR-MRI and FDG-PET were evaluated using a novel "pseudo-control" normalization approach to determine which features best distinguished dysplastic from normal-appearing cortex. Using the Multi-centre Epilepsy Lesion Detection groups machine-learning detection method with the addition of FDG-PET, neural network classifiers were then trained and tested on MRI+PET features, MRI-only and PET-only. The proportion of patients whose BOSD was overlapped by the top output cluster, and the top five output clusters, were assessed. ResultsCortical and subcortical hypometabolism on FDG-PET were superior in discriminating dysplastic from normal-appearing cortex compared to MRI features. When the BOSD detector was trained on MRI+PET features, 87% BOSDs were overlapped by one of the top five clusters (69% top cluster) in the training set, 76% in the prospective test set (71% top cluster) and 75% in the published test set (42% top cluster). Cluster overlap was similar when the detector was trained and tested on PET-only features but lower when trained and tested on MRI-only features. ConclusionDetection of BOSD is possible using established MRI-based automated detection methods, supplemented with FDG-PET features and trained on a BOSD-specific cohort. In clinical practice, an MRI+PET BOSD detector could improve assessment and outcomes in seemingly MRI-negative patients being considered for epilepsy surgery.

BackgroundIn glioblastoma (GBM), promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) is associated with beneficial chemotherapy but has not been accurately evaluated based on radiological and pathological sections. To develop and validate an MRI and pathology image-based deep learning radiopathomics model for predicting MGMT promoter methylation in patients with GBM. MethodsA retrospective collection of pathologically confirmed isocitrate dehydrogenase (IDH) wild-type GBM patients (n=207) from three centers was performed, all of whom underwent MRI scanning within 2 weeks prior to surgery. The pre-trained ResNet50 was used as the feature extractor. Features of 1024 dimensions were extracted from MRI and pathological images, respectively, and the features were screened for modeling. Then feature fusion was performed by calculating the normalized multimode MRI fusion features and pathological features, and prediction models of MGMT based on deep learning radiomics, pathomics, and radiopathomics (DLRM, DLPM, DLRPM) were constructed and applied to internal and external validation cohorts. ResultsIn the training, internal and external validation cohorts, the DLRPM further improved the predictive performance, with a significantly better predictive performance than the DLRM and DLPM, with AUCs of 0.920 (95% CI 0.870-0.968), 0.854 (95% CI 0.702-1), and 0.840 (95% CI 0.625-1). ConclusionWe developed and validated cross-scale radiology and pathology models for predicting MGMT methylation status, with DLRPM predicting the best performance, and this cross-scale approach paves the way for further research and clinical applications in the future.

Alzheimers Disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. In 2024, in the US alone, it affected approximately 1 in 9 people aged 65 and older, equivalent to 6.9 million individuals. Early detection and accurate AD diagnosis are crucial for improving patient outcomes. Magnetic resonance imaging (MRI) has emerged as a valuable tool for examining brain structure and identifying potential AD biomarkers. This study performs predictive analyses by employing machine learning techniques to identify key brain regions associated with AD using numerical data derived from anatomical MRI scans, going beyond standard statistical methods. Using the Random Forest Algorithm, we achieved 92.87% accuracy in detecting AD from Mild Cognitive Impairment and Cognitive Normals. Subgroup analyses across nine sex- and age-based cohorts (69-76 years, 77-84 years, and unified 69-84 years) revealed the hippocampus, amygdala, and entorhinal cortex as consistent top-rank predictors. These regions showed distinct volume reductions across age and sex groups, reflecting distinct age- and sex-related neuroanatomical patterns. For instance, younger males and females (aged 69-76) exhibited volume decreases in the right hippocampus, suggesting its importance in the early stages of AD. Older males (77-84) showed substantial volume decreases in the left inferior temporal cortex. Additionally, the left middle temporal cortex showed decreased volume in females, suggesting a potential female-specific influence, while the right entorhinal cortex may have a male-specific impact. These age-specific sex differences could inform clinical research and treatment strategies, aiding in identifying neuroanatomical markers and therapeutic targets for future clinical interventions.

Timely intervention for Alzheimers disease (AD) requires early detection. The development of immunotherapies targeting amyloid-beta and tau underscores the need for accessible, time-efficient biomarkers for early diagnosis. Here, we directly applied our previously developed MRI-based deep learning model for AD to the large Chinese SILCODE cohort (722 participants, 1,105 brain MRI scans). The model -- initially trained on North American data -- demonstrated robust cross-ethnic generalization, without any retraining or fine-tuning, achieving an AUC of 91.3% in AD classification with a sensitivity of 95.2%. It successfully identified 86.7% of individuals at risk of AD progression more than 5 years in advance. Individuals identified as high-risk exhibited significantly shorter median progression times. By integrating an interpretable deep learning brain risk map approach, we identified AD brain subtypes, including an MCI subtype associated with rapid cognitive decline. The models risk scores showed significant correlations with cognitive measures and plasma biomarkers, such as tau proteins and neurofilament light chain (NfL). These findings underscore the exceptional generalizability and clinical utility of MRI-based deep learning models, especially in large and diverse populations, offering valuable tools for early therapeutic intervention. The model has been made open-source and deployed to a free online website for AD risk prediction, to assist in early screening and intervention.

Cerebral aneurysm is a silent yet prevalent condition that affects a substantial portion of the global population. Aneurysms can develop due to various factors and present differently, necessitating diverse treatment approaches. Choosing the appropriate treatment upon diagnosis is paramount, as the severity of the disease dictates the course of action. The vulnerability of an aneurysm, particularly in the circle of Willis, is a critical concern; rupture can lead to irreversible consequences, including death. The primary objective of this study is to predict the rupture status of cerebral aneurysms using a comprehensive dataset that includes clinical, morphological, and hemodynamic data extracted from blood flow simulations of patients with actual vessels. Our goal is to provide valuable insights that can aid in treatment decision-making and potentially save the lives of future patients. Diagnosing and predicting the rupture status of aneurysms based solely on brain scans poses a significant challenge, often with limited accuracy, even for experienced physicians. However, harnessing statistical and machine learning (ML) techniques can enhance rupture prediction and treatment strategy selection. We employed a diverse set of supervised and unsupervised algorithms, training them on a database comprising over 700 cerebral aneurysms, which included 55 different parameters: 3 clinical, 35 morphological, and 17 hemodynamic features. Two of our models including stochastic gradient descent (SGD) and multi-layer perceptron (MLP) achieved a maximum area under the curve (AUC) of 0.86, a precision rate of 0.86, and a recall rate of 0.90 for prediction of cerebral aneurysm rupture. Given the sensitivity of the data and the critical nature of the condition, recall is a more vital parameter than accuracy and precision; our study achieved an acceptable recall score. Key features for rupture prediction included ellipticity index, low shear area ratio, and irregularity. Additionally, a one-dimensional CNN model predicted rupture status along a continuous spectrum, achieving 0.78 accuracy on the testing dataset, providing nuanced insights into rupture propensity.